1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Introduction
2.2. Define: Research Objective
2.3. Determine: Research Design
2.4. Prepare: Research Instrument
2.5. Collect: Data Source
2.6. Analyze: Data Interpretation
2.7. Formulate: Data Verification
2.8. Publish: Research Report
2.9. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19

6. Castleman Disease Treatment Market, by Disease Type
6.1. Introduction
6.2. Multicentric Castleman's Disease
6.3. Unicentric Castleman's Disease

7. Castleman Disease Treatment Market, by Indication
7.1. Introduction
7.2. Angiofollicular Lymph Node Hyperplasia
7.3. Angiomatous Lymphoid
7.4. Castleman Tumor
7.5. Giant Benign Lymphoma
7.6. Giant Lymph Node Hyperplasia
7.7. Hamartoma of the Lyphatics

8. Castleman Disease Treatment Market, by Therapy
8.1. Introduction
8.2. Antiviral Drugs
8.3. Chemotherapy
8.4. Corticosteroids
8.5. Immunotherapy
8.6. Monoclonal Antibodies
8.7. Radiation Therapy

9. Castleman Disease Treatment Market, by Application
9.1. Introduction
9.2. Ambulatory Surgical Centers
9.3. Infectious Diseases

10. California Castleman Disease Treatment Market

11. Florida Castleman Disease Treatment Market

12. Illinois Castleman Disease Treatment Market

13. New York Castleman Disease Treatment Market

14. Ohio Castleman Disease Treatment Market

15. Pennsylvania Castleman Disease Treatment Market

16. Texas Castleman Disease Treatment Market

17. Competitive Landscape
17.1. FPNV Positioning Matrix
17.1.1. Quadrants
17.1.2. Business Strategy
17.1.3. Product Satisfaction
17.2. Market Ranking Analysis
17.3. Market Share Analysis, By Key Player
17.4. Competitive Scenario
17.4.1. Merger & Acquisition
17.4.2. Agreement, Collaboration, & Partnership
17.4.3. New Product Launch & Enhancement
17.4.4. Investment & Funding
17.4.5. Award, Recognition, & Expansion

18. Company Usability Profiles
18.1. AbbVie Inc.
18.2. Amgen Inc.
18.3. Bayer AG
18.4. Boehringer Ingelheim GmbH
18.5. Bristol-Myers Squibb
18.6. EUSA Pharma, Inc.
18.7. F. Hoffmann-La Roche Ltd.
18.8. Gilead Sciences, Inc.
18.9. GlaxoSmithKline PLC
18.10. Hospira, Inc.
18.11. Incyte Corporation
18.12. Janssen Global Services, LLC (Johnson & Johnson Services, Inc.)
18.13. Jazz Pharmaceuticals, Inc
18.14. LGM Pharma
18.15. Merck & Co., Inc.
18.16. NPS Pharmaceuticals, Inc,
18.17. Octapharma AG
18.18. Pfizer, Inc.
18.19. Relypsa, Inc.
18.20. Sanofi S.A.
18.21. Santa Cruz Biotechnology, Inc
18.22. Senhwa Biosciences
18.23. Triveni Interchem Private Limited

19. Appendix
19.1. Discussion Guide
19.2. License & Pricing

List of Figures

FIGURE 1. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET: MARKET DYNAMICS
FIGURE 3. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2020 VS 2027 (%)
FIGURE 4. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2020 VS 2027 (USD MILLION)
FIGURE 5. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2027
FIGURE 6. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MULTICENTRIC CASTLEMAN'S DISEASE, 2018-2027 (USD MILLION)
FIGURE 7. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MULTICENTRIC CASTLEMAN'S DISEASE, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 8. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY UNICENTRIC CASTLEMAN'S DISEASE, 2018-2027 (USD MILLION)
FIGURE 9. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY UNICENTRIC CASTLEMAN'S DISEASE, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 10. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2020 VS 2027 (%)
FIGURE 11. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2020 VS 2027 (USD MILLION)
FIGURE 12. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2027
FIGURE 13. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA, 2018-2027 (USD MILLION)
FIGURE 14. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 15. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ANGIOMATOUS LYMPHOID, 2018-2027 (USD MILLION)
FIGURE 16. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ANGIOMATOUS LYMPHOID, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 17. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CASTLEMAN TUMOR, 2018-2027 (USD MILLION)
FIGURE 18. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CASTLEMAN TUMOR, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 19. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY GIANT BENIGN LYMPHOMA, 2018-2027 (USD MILLION)
FIGURE 20. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY GIANT BENIGN LYMPHOMA, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 21. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY GIANT LYMPH NODE HYPERPLASIA, 2018-2027 (USD MILLION)
FIGURE 22. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY GIANT LYMPH NODE HYPERPLASIA, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 23. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HAMARTOMA OF THE LYPHATICS, 2018-2027 (USD MILLION)
FIGURE 24. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HAMARTOMA OF THE LYPHATICS, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 25. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2020 VS 2027 (%)
FIGURE 26. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2020 VS 2027 (USD MILLION)
FIGURE 27. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2027
FIGURE 28. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ANTIVIRAL DRUGS, 2018-2027 (USD MILLION)
FIGURE 29. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ANTIVIRAL DRUGS, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 30. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2027 (USD MILLION)
FIGURE 31. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 32. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2027 (USD MILLION)
FIGURE 33. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 34. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2027 (USD MILLION)
FIGURE 35. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 36. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2027 (USD MILLION)
FIGURE 37. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 38. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY RADIATION THERAPY, 2018-2027 (USD MILLION)
FIGURE 39. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 40. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2020 VS 2027 (%)
FIGURE 41. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2020 VS 2027 (USD MILLION)
FIGURE 42. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2027
FIGURE 43. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2027 (USD MILLION)
FIGURE 44. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 45. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2027 (USD MILLION)
FIGURE 46. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INFECTIOUS DISEASES, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 47. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET: FPNV POSITIONING MATRIX
FIGURE 48. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 49. COMPETITIVE SCENARIO ANALYSIS IN UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET, BY TYPE

List of Tables

TABLE 1. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
TABLE 3. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 4. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MULTICENTRIC CASTLEMAN'S DISEASE, BY STATE, 2018-2027 (USD MILLION)
TABLE 5. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY UNICENTRIC CASTLEMAN'S DISEASE, BY STATE, 2018-2027 (USD MILLION)
TABLE 6. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 7. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA, BY STATE, 2018-2027 (USD MILLION)
TABLE 8. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ANGIOMATOUS LYMPHOID, BY STATE, 2018-2027 (USD MILLION)
TABLE 9. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CASTLEMAN TUMOR, BY STATE, 2018-2027 (USD MILLION)
TABLE 10. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY GIANT BENIGN LYMPHOMA, BY STATE, 2018-2027 (USD MILLION)
TABLE 11. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY GIANT LYMPH NODE HYPERPLASIA, BY STATE, 2018-2027 (USD MILLION)
TABLE 12. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HAMARTOMA OF THE LYPHATICS, BY STATE, 2018-2027 (USD MILLION)
TABLE 13. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2018-2027 (USD MILLION)
TABLE 14. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ANTIVIRAL DRUGS, BY STATE, 2018-2027 (USD MILLION)
TABLE 15. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY STATE, 2018-2027 (USD MILLION)
TABLE 16. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY STATE, 2018-2027 (USD MILLION)
TABLE 17. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY STATE, 2018-2027 (USD MILLION)
TABLE 18. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY STATE, 2018-2027 (USD MILLION)
TABLE 19. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY STATE, 2018-2027 (USD MILLION)
TABLE 20. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 21. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY STATE, 2018-2027 (USD MILLION)
TABLE 22. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INFECTIOUS DISEASES, BY STATE, 2018-2027 (USD MILLION)
TABLE 23. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET: SCORES
TABLE 24. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET: BUSINESS STRATEGY
TABLE 25. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET: PRODUCT SATISFACTION
TABLE 26. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET: RANKING
TABLE 27. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 28. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET: MERGER & ACQUISITION
TABLE 29. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 30. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 31. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET: INVESTMENT & FUNDING
TABLE 32. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 33. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET: LICENSE & PRICING

Companies Mentioned

AbbVie Inc.
Amgen Inc.
Bayer AG
Boehringer Ingelheim GmbH
Bristol-Myers Squibb
EUSA Pharma, Inc.
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
GlaxoSmithKline PLC
Hospira, Inc.
Incyte Corporation
Janssen Global Services, LLC (Johnson & Johnson Services, Inc.)
Jazz Pharmaceuticals, Inc
LGM Pharma
Merck & Co., Inc.
NPS Pharmaceuticals, Inc,
Octapharma AG
Pfizer, Inc.
Relypsa, Inc.
Sanofi S.A.
Santa Cruz Biotechnology, Inc
Senhwa Biosciences
Triveni Interchem Private Limited